Pro-Dex (NASDAQ:PDEX) Stock Rating Upgraded by StockNews.com

Pro-Dex (NASDAQ:PDEX) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report issued on Saturday.

Separately, Ascendiant Capital Markets upped their price objective on shares of Pro-Dex from $30.00 to $52.00 and gave the stock a “buy” rating in a report on Monday, November 11th.

Pro-Dex Price Performance

NASDAQ PDEX opened at $49.44 on Friday. The company has a current ratio of 3.41, a quick ratio of 1.94 and a debt-to-equity ratio of 0.36. The company has a fifty day simple moving average of $40.23 and a 200 day simple moving average of $28.02. The company has a market cap of $161.17 million, a P/E ratio of 32.10 and a beta of 0.56. Pro-Dex has a 1 year low of $16.18 and a 1 year high of $54.84.

Insider Buying and Selling at Pro-Dex

In other Pro-Dex news, CFO Alisha Charlton sold 1,000 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $40.02, for a total value of $40,020.00. Following the completion of the sale, the chief financial officer now directly owns 15,339 shares of the company’s stock, valued at $613,866.78. This represents a 6.12 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 47.50% of the company’s stock.

Institutional Trading of Pro-Dex

Hedge funds have recently bought and sold shares of the stock. FMR LLC boosted its holdings in Pro-Dex by 34.9% in the 3rd quarter. FMR LLC now owns 3,973 shares of the medical instruments supplier’s stock valued at $119,000 after purchasing an additional 1,028 shares during the period. Renaissance Technologies LLC raised its stake in shares of Pro-Dex by 7.9% in the 2nd quarter. Renaissance Technologies LLC now owns 12,240 shares of the medical instruments supplier’s stock valued at $240,000 after buying an additional 900 shares in the last quarter. Bard Associates Inc. raised its stake in shares of Pro-Dex by 17.6% in the 3rd quarter. Bard Associates Inc. now owns 13,596 shares of the medical instruments supplier’s stock valued at $406,000 after buying an additional 2,031 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Pro-Dex by 9.1% in the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock valued at $819,000 after buying an additional 2,296 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Pro-Dex by 5.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 63,036 shares of the medical instruments supplier’s stock valued at $1,238,000 after buying an additional 3,067 shares in the last quarter. 15.28% of the stock is owned by institutional investors.

Pro-Dex Company Profile

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.